Japan's Tanabe Pharma, Switzerland's Covagen In Biospecific-Protein Pact
This article was originally published in PharmAsia News
Tanabe Pharma and Covagen have agreed to a collaboration and licensing arrangement the calls for the Japan drug maker to provide $5.2 million up front for research and development of the Swiss company's biospecific proteins. Under the arrangement,
You may also be interested in...
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.
With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.